We are live on ! Find out more
WHWK

Whitehawk Therapeutics

70 hedge funds and large institutions have $107M invested in Whitehawk Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 18

3.91% less ownership

Funds ownership: 62.59%58.68% (-3.9%)

7% less funds holding

Funds holding: 7570 (-5)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

30% less call options, than puts

Call options by funds: $14K | Put options by funds: $20K

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

44% less capital invested

Capital invested by funds: $192M → $107M (-$85.2M)

Holders
70
Holders Change
-5
Holders Change %
-6.67%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
8
Increased
21
Reduced
18
Closed
13
Calls
$14K
Puts
$20K
Net Calls
-$6K
Net Calls Change
-$1.33M

WHWK Hedge Fund Activity: Q1 2023 in Review

70 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2023, worth a combined $107M — down 44% from $192M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of WHWK and 8 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 21 added.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $4.89M. The largest seller was RTW Investments, exiting entirely with an estimated $9.81M sold.

  • 70 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2023, down from 75 in Q4 2022.
  • Funds reported $107M of Whitehawk Therapeutics stock for Q1 2023, down 44% quarter-over-quarter.
  • 8 funds opened new Whitehawk Therapeutics positions in Q1 2023 and 13 closed out, a net change of -5 holders.
  • The largest Whitehawk Therapeutics buyer in Q1 2023 was Janus Henderson Group, an estimated $4.89M added.
  • The largest Whitehawk Therapeutics seller in Q1 2023 was RTW Investments, an estimated $9.81M sold.

Based on aggregated 13F filings for Q1 2023.